Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 31, 2014
Pharmacy Choice - News - U.S. Pharmaceutical Industry - July 31, 2014

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/30/14 - "Assembly for a Drug Delivery Device, Piston Rod and Drug Delivery Device" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Nzike, Philippe; Raab, Steffen; Dasbach, Uwe; Boeser, Uwe; Bruggemann, Ulrich; Soares, Francisco, filed on February 27, 2014, was made available online on July 17, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents
7/30/14 - "Biodegradable Carrier with Adjustable Zeta Potentials and Particle Sizes, Method for Making the Same, and Pharmaceutical Composition Comprising the...
"Biodegradable Carrier with Adjustable Zeta Potentials and Particle Sizes, Method for Making the Same, and Pharmaceutical Composition Comprising the Same" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors LIN, YEE-SHIN; CHEN, YU-HUNG, filed on June 21, 2013, was made
7/30/14 - "Biodegradable High-Efficiency Dengue Vaccine, Method for Making the Same, and Pharmaceutical Composition Comprising the Same" in Patent Application...
"Biodegradable High-Efficiency Dengue Vaccine, Method for Making the Same, and Pharmaceutical Composition Comprising the Same" in Patent Application Approval Process. By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors LIN, YEE-SHIN; CHEN, YU-HUNG, filed on June 24, 2013, was made available online on July 17
7/30/14 - "Compositions and Methods for Treating Centrally Mediated Nausea and Vomiting" in Patent Application Approval Process
This patent application is assigned to Helsinn Healthcare S.A.. Examples of 5- HT.sub.3 antagonists include ondansetron, marketed by GlaxoSmithKline, and palonosetron, developed by Helsinn Healthcare. See PCT publications WO 2004/ 045615 and 2004/ 073714 from Helsinn Healthcare.
7/30/14 - "Temperature-Dependent Insertion of Genetic Material into Genomic DNA" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Vaccine Weekly A patent application by the inventors JACOBS, Bertram; KIBLER, Karen, filed on January 7, 2014, was made available online on July 17, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or in
7/30/14 - AcelRX Selling Off On FDA Reexamination; U.S. FDA Grants Approval for IMBRUVICA
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 28, 2014.{ nfg} Shares of AcelRx Pharmaceuticals are selling off sharply monday morning after a blow from the FDA to Zalviso. AcelRx made the announcement at an unusual time: 9:59 p.m. ET Friday. The FDA is looking for more information on how to u
7/30/14 - ADMP Awaits Decision, REGN Can Catch Your Eye, SQNM Does A Deal, ZLTQ Goes Cool
WASHINGTON- Adamis Pharmaceuticals Corp.' s New Drug Application for EPINEPHRINE INJECTION, USP, 1:10 00 for the emergency treatment of allergic reactions including anaphylaxis has been accepted for review by the FDA. Fate Therapeutics Inc. is all set to begin a phase 1 b study of PROHEMA in pediatric patients undergoing hematopoietic stem cell...
7/30/14 - Aegerion Pharmaceuticals Appoints Craig Fraser as Chief Operating Officer
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Craig Fraser has been appointed as Chief Operating Officer. Prior to his appointment as COO, Mr. Fraser served as President, U.S. and Internationa
7/30/14 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; FDA Safety Communication Readership Survey
SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled " FDA Safety Communication Readership Survey" has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 C
7/30/14 - Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion? in the new facility.
Ampio Pharmaceuticals, Inc. today announced a positive written response from the FDA in regards to the company's plans to begin production of Ampion TM in our new drug manufacturing facility. Mr, Macaluso, Ampio's CEO, noted that, "This decision by the FDA was greatly encouraging to our management team as it supports the quality of our efforts to
7/30/14 - Animal Health Institute Asks FDA to Enforce Laws Against Illegal Animal Drug Compounding [Manufacturing Close - Up]
The Animal Health Institute, along with the experts in the field of animal health and veterinary medicine brought together consumers, media, veterinary experts, policymakers and industry stakeholders for a teleconference and two Congressional briefings calling for greater action by the U.S. Food and Drug Administration on illegal animal drug...
7/30/14 - AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1 b clinical trial with AtheroNova's lead compound, AHRO-001. This Phase 1 b tr
7/30/14 - Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium's Actimab-A Clinical Trial
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. M. Yair Levy, MD, Medical Director of Hematologic Malignancy Clinical Research, B
7/30/14 - Bio Blast Pharma Prices Initial Public Offering of $35,200,000 of Ordinary Shares
Bio Blast Pharma Ltd., a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, announced today the pricing of its initial public offering of 3,200,000 ordinary shares at an initial public offering price of $11.00 per share. A registration statement...
7/30/14 - BioMarin Sells Priority Review Voucher for $67.5 Million
BioMarin Pharmaceutical Inc. today announced that it has sold the Rare Pediatric Disease Priority Review Voucher it obtained in February of this year. The Company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. BioMarin received $67.5 million from Regeneron Ireland, an ind
7/30/14 - BrainStorm's Clinical Trial is Fast-Tracked to Phase IIa; CEL-SCI Expands Its Phase III Head and Neck Cancer Trial
The trial, which will evaluate the safety and preliminary efficacy of BrainStorm s NurOwn stem cell therapy candidate, will be launched immediately at the Hadassah Medical Center in Jerusalem. The Ministry of Health approved acceleration to a Phase IIa trial based on evaluation of only 12 of the initial cohort of 24 patients in the company s
7/30/14 - Celladon to Report Second Quarter 2014 Results on August 7, 2014
Celladon Corporation, a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it will report its results for the second quarter ended June 30, 2014 on Thursday, August 7, 2014. Celladon is a clinical-stage biotechnology company applying its leadership pos
7/30/14 - Cold Genesys Raises $13.57 Million in a Series A Round of Financing to Accelerate Its Ongoing Phase II/III Clinical Trial for Bladder Cancer
Cold Genesys, Inc., a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer, announced today that it has secured Series A financing of $13.57 million from Ally Bridge Group. The addition of Ally Bridge Group as a strategic investor at this critical juncture of our CG0070 program for NMIBC not only enables us to
7/30/14 - Competition and the Cost of Medicare's Prescription Drug Program
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 substantially expanded the federal Medicare program by creating the prescription drug benefit known as Part D. In fiscal year 2013, Medicare Part D covered 39 million people. The federal government spent $59 billion net of premiums on Part D in that year; after accounting fo
7/30/14 - CORTEX PHARMACEUTICALS INC/DE/ - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
In order to expand the Company's respiratory disorders program, on August 10, 2012, pursuant to an Agreement and Plan of Merger by and among Pier Pharmaceuticals, Inc., a privately-held corporation, Pier Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of Cortex, and Cortex, Merger Sub merged with and into Pier and Pier becam
7/30/14 - Cosmo reports excellent first half
Lainate, Italy- 30 July 2014- Cosmo Pharmaceuticals S.p.A. announced today its half-year results for the period ended 30 June 2014.. Uceris net revenues in the USA have exceeded all expectations CB-03-01 phase II for acne was successfully concluded. The FDA agreed to the clinical development plan as a medical device of the new product SIC 8000,
7/30/14 - Depomed Sets Date to Report 2nd Quarter 2014 Financial Results [Professional Services Close - Up]
Depomed will release second quarter fiscal year 2014 financial results after the market closes on August 6. The conference call will also be available via a live webcast on the investor relations section of Depomed's website. Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.
7/30/14 - DGAP-News: Novavax to Host Conference Call to Discuss Second Quarter 2014 Financial Results on August 6, 2014
DGAP-News: Novavax, Inc. Novavax to Host Conference Call to Discuss Second Quarter 2014 Financial Results on August 6, 2014 30.07. 2014/ 22:10- ROCKVILLE, Md., 2014-07-30 22:10 CEST Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development an
7/30/14 - DiaMedica to Present at InvestMNt Conference on August 6, 2014
DiaMedica Inc., a clinical stage biopharmaceutical company primarily focused on the development of novel, first-in-class therapies for metabolic disorders, kidney dysfunction and orphan diseases, announced today that the Company will present at the 2014 InvestMNt conference sponsored by CFA Society Minnesota. DiaMedica Inc. is a publicly traded...
7/30/14 - Donna Ambrosino Joins ClearPath Vaccines Company as Chief Medical Officer
By a News Reporter-Staff News Editor at Vaccine Weekly ClearPath Development Company announced that Donna Ambrosino, MD, has joined the company's subsidiary, ClearPath Vaccines Company, as its chief medical officer. "Donna has an extensive track record in leading the development of biological products from discovery through proof-of-concept in r
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415